Explore the words cloud of the StaphIMPACT project. It provides you a very rough idea of what is the project "StaphIMPACT" about.
The following table provides information about the project.
MICREOS HUMAN HEALTH BV
|Coordinator Country||Netherlands [NL]|
|Total cost||3˙565˙625 €|
|EC max contribution||2˙495˙937 € (70%)|
1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
|Duration (year-month-day)||from 2019-07-01 to 2021-06-30|
Take a look of project's partnership.
|1||MICREOS HUMAN HEALTH BV||NL (S GRAVENHAGE)||coordinator||2˙495˙937.00|
According to the WHO, antibiotic resistance is one of humanity’s biggest health threats, claiming ~10 million extra deaths per year and US$100 trillion by 2050, unless alternatives to antibiotics are developed. Micreos has developed the world’s first targeted antibacterial products, set to replace antibiotics. With its endolysin technology, for the first time it is possible to kill only the unwanted bacteria, regardless of resistance. Micreos’ endolysin technology was chosen as Europe’s most relevant Innovation 2018 (Ideas from Europe). Its first lead endolysin, SA.100, kills only Staphylococcus aureus, including the resistant MRSA. Soft-launched under the Gladskin brand in the Netherlands, it’s having life-changing impact for thousands of people with inflammatory skin conditions caused or aggravated by S. aureus, including eczema, acne, rosacea and Hyper IgE syndrome. Micreos also develops products for diabetic wound infections and a skin cancer triggered by S. aureus. Micreos owns all relevant IP and know-how on its technology and produces its compounds and Gladskin products at small-scale at its facilities in the Netherlands. With this SMEi, Micreos prepares for full roll-out into the EU markets of its SA.100/Gladskin. This includes scale-up of production capacity, strengthening clinical evidence and communication of results to KOLs and relevant stakeholders. Leading pharma and cosmetics companies have expressed interest to in-license Micreos’ technology for particular indications. Relevant markets are the consumer’s skin care market ($177b by 2024; CAGR 4.7%) and dermatology market ($19.8b by 2023; CAGR 9.1%.). Own contribution by Micreos for this SMEi is already secured. This SMEi enables Micreos to take final steps for EU-wide roll-out, driving employment growth and company profitability, and helping people suffering from inflammatory skin conditions.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "STAPHIMPACT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "STAPHIMPACT" are provided by the European Opendata Portal: CORDIS opendata.